|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.38 USD | +2.24% |
|
+0.87% | -15.63% |
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
Revenues | - | - | - | 925K |
Total Revenues | - | - | - | 925K |
Cost of Goods Sold, Total | 42.26M | 47.5M | 44.39M | 60.82M |
Gross Profit | -42.26M | -47.5M | -44.39M | -59.89M |
Selling General & Admin Expenses, Total | 8.27M | 9.01M | 11.19M | 22.61M |
Other Operating Expenses, Total | 8.27M | 9.01M | 11.19M | 22.61M |
Operating Income | -50.53M | -56.52M | -55.58M | -82.5M |
Interest Expense, Total | - | -2K | -12K | -12K |
Interest And Investment Income | 17K | 1.34M | 2.95M | 8.47M |
Net Interest Expenses | 17K | 1.34M | 2.94M | 8.46M |
Other Non Operating Income (Expenses) | - | -7K | -28K | -994K |
EBT, Excl. Unusual Items | -50.52M | -55.19M | -52.67M | -75.04M |
Asset Writedown | - | - | - | -100K |
Other Unusual Items | - | - | 16.36M | - |
EBT, Incl. Unusual Items | -50.52M | -55.19M | -36.32M | -75.14M |
Earnings From Continuing Operations | -50.52M | -55.19M | -36.32M | -75.14M |
Net Income to Company | -50.52M | -55.19M | -36.32M | -75.14M |
Net Income - (IS) | -50.52M | -55.19M | -36.32M | -75.14M |
Preferred Dividend and Other Adjustments | - | - | -49.97M | - |
Net Income to Common Incl Extra Items | -50.52M | -55.19M | 13.65M | -75.14M |
Net Income to Common Excl. Extra Items | -50.52M | -55.19M | 13.65M | -75.14M |
Per Share Items | ||||
Net EPS - Basic | -12.47 | -10.58 | 27.76 | -4.28 |
Basic EPS - Continuing Operations | -12.47 | -10.58 | 27.76 | -4.28 |
Basic Weighted Average Shares Outstanding | 4.05M | 5.22M | 492K | 17.57M |
Net EPS - Diluted | -12.47 | -10.58 | 2.93 | -4.28 |
Diluted EPS - Continuing Operations | -12.47 | -10.58 | 2.93 | -4.28 |
Diluted Weighted Average Shares Outstanding | 4.05M | 5.22M | 4.66M | 17.57M |
Normalized Basic EPS | -7.79 | -6.61 | -66.93 | -2.67 |
Normalized Diluted EPS | -7.79 | -6.61 | -7.07 | -2.67 |
Supplemental Items | ||||
EBITDA | -49.59M | -53.32M | -52.29M | -79.26M |
EBITA | -50.53M | -56.52M | -55.58M | -82.5M |
EBIT | -50.53M | -56.52M | -55.58M | -82.5M |
EBITDAR | -44.85M | -49.66M | -50.99M | -76.36M |
Normalized Net Income | -31.57M | -34.49M | -32.92M | -46.9M |
Interest on Long-Term Debt | - | 2K | 12K | 12K |
Supplemental Operating Expense Items | ||||
General and Administrative Expenses | 8.27M | 9.01M | 11.19M | 22.61M |
Research And Development Expense From Footnotes | 42.26M | 47.5M | 44.39M | 60.92M |
Net Rental Expense, Total | 4.74M | 3.67M | 1.3M | 2.9M |
Imputed Operating Lease Interest Expense | - | 11.85K | 12.64K | 20.32K |
Imputed Operating Lease Depreciation | - | 3.65M | 1.28M | 2.88M |
Stock-Based Comp., COGS (Total) | 474K | 732K | 897K | 4.51M |
Stock-Based Comp., G&A Exp. (Total) | 422K | 520K | 521K | 3.81M |
Total Stock-Based Compensation | 896K | 1.25M | 1.42M | 8.32M |
- Stock Market
- Equities
- NGNE Stock
- Financials Neurogene Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















